INTERNATIONAL PATENT: JANSSEN BIOTECH, INC. FILES APPLICATION FOR "FIRST LINE TREATMENT IN EGFR EXON 20 INSERTION-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER"

GENEVA, April 19 -- JANSSEN BIOTECH, INC. (800/850 Ridgeview DriveHorsham, Pennsylvania 19044) filed a patent application (PCT/IB2024/059967) for "FIRST LINE TREATMENT IN EGFR EXON 20 INSERTION-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER" on Oct 11, 2024. With publication no. WO/2025/079020, the details related to the patent application was published on Apr 17, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): KNOBLAUCH, Roland (1400 McKean RoadSpring House, Pennsylvania 19477)

Abstract: The present disclosure provides methods for treating EGFR-positive non-small cell lung cancer (NSCLC) in...